Select Small Cap BioPharma Currents This *Morning

by: StockMatusow

ImmunoCellular Therapeutics (NYSEMKT:IMUC) reported yesterday that Manish Singh resigned his position as the company's CEO as well as his position as president and a director. He had been CEO since 2008 and previously managed medical industry investments for a venture capital firm.

Last week ImmunoCellular reported that its second quarter loss widened to $6.5 million from $1.6 million a year earlier. The company reported no revenue in either period but said it had enough cash, $11.3 million, to fund 12 months of operations.

This morning, the stock is currently trading at $2.49, down $0.42 (14.43%).

Pluristem Therapeutics (PSTI) is rallying once again this morning on news that the company has renewed a five-year Collaborative Research Agreement with the Berlin-Brandenburg Center for Regenerative Therapy (BCRT) at Charite - University Medicine Berlin. The original five-year Collaborative Research Agreement was signed between the parties in 2007.

Pluristem has seen its stock price rally in one month more than 90%. The company has applied for the approval of its bone marrow drug in the U.S., as well as entering into studies in other regions around the globe.

Shares of the company this morning are currently trading at $4.27, up $0.27 (6.70%).

Antares Pharma (NASDAQ:ATRS) has been recently seeing its stock rebound strongly in anticipation of its NDA filing for Vibex MTX. The stock rallied sharply in July after Antares announced positive results from a human factors usability study for Vibex MTX.

Shares of Antares are trading this morning at $4.03, up $0.07 (1.64%).

According to a Reza Ganjavi in a report released today, the following institutions either initiated or bought additional shares of Arena Pharma (NASDAQ:ARNA) recently:

Oppenheimer Funds (3,000,000 shares), Cupps Capital (1,001,772 shares), Vanguard Groups (3,535,204 shares), State Street (3,195,22 shares.), Wellington Management (3,099,42 shares), and Morgan Stanley (NYSE:MS) (1,561,429 shares).

According to Ganjavi based on the latest institutional holdings report issued June 30, Arena saw a net increase of 18,550,184 shares while both Vivus (NASDAQ:VVUS) and Orexigen (NASDAQ:OREX) saw a net decrease of 5,717,430 and 1,665,947 shares respectively.

Arena shares are currently trading this morning at $8.02, down $0.01 (0.06%), while Vivus shares are trading at $20.85, up $0.09 (0.42%), with Orexigen shares trading at $3.82, down $0.21 (5.21%).

Disclosure: I am long ATRS. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: Disclaimer: This article is intended for informational and entertainment use only, and should not be construed as professional investment advice. They are my opinions only. Trading stocks is risky - always be sure to know and understand your risk tolerance. You can incur substantial financial losses in any trade or investment. Always do your own due diligence before buying and selling any stock, and/or consult with a licensed financial adviser.